



HAL
open science

Physico-chemical characterization and immunomodulatory activity of bifidobacterium longum exopolysaccharide polyelectrolyte multilayer coatings

Romain Bagnol, Claudia Siverino, Vincent Barnier, Liam O'mahony, Dirk W. Grijpma, David Eglin, T. Fintan Moriarty

► To cite this version:

Romain Bagnol, Claudia Siverino, Vincent Barnier, Liam O'mahony, Dirk W. Grijpma, et al.. Physico-chemical characterization and immunomodulatory activity of bifidobacterium longum exopolysaccharide polyelectrolyte multilayer coatings. *Biomacromolecules*, 2023, 24 (12), pp.5589 à 5604. 10.1021/acs.biomac.3c00516 . emse-04594828

HAL Id: emse-04594828

<https://hal-emse.ccsd.cnrs.fr/emse-04594828v1>

Submitted on 14 Oct 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Target journal: ACS Biomacromolecules

Title: Physico-chemical characterization and immunomodulatory activity of bifidobacterium longum exopolysaccharide polyelectrolyte multilayer coatings

Authors: Romain Bagnol^{1,2}, Claudia Siverino¹, Vincent Barnier³, Liam O'Mahony⁴, Dirk Grijpma², David Eglin^{2,5}, T. Fintan Moriarty¹

Affiliations:

¹ AO Research Institute Davos, Davos, Switzerland,

² Technical Medical Centre, Department of Advanced Organ Engineering and Therapeutics, Faculty of Science and Technology, University of Twente, Drienerlolaan 5, 7522 NB Enschede, the Netherlands,

³ Mines Saint-Etienne, CNRS, UMR 5307 LGF, Centre SMS, F-42023 Saint-Etienne, France,

⁴ Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland,

⁵ Mines Saint-Étienne, Univ Lyon, Univ Jean Monnet, INSERM, U1059 Sainbiose, Saint-Étienne F - 42023 France.

Keywords: *Bifidobacterium Longum*, polyelectrolyte, exopolysaccharide.

1 Abstract (150 words)

2 Immunoregulatory polysaccharides from probiotic bacteria have potential for application in biomedical
3 engineering. Here, a negatively charged exopolysaccharide from *Bifidobacterium longum* with confirmed
4 immunoregulatory activity (EPS624), is applied in multilayered polyelectrolyte coatings with positively
5 charged chitosan.

6 EPS624 and coatings (1, 5, 10 layers, and alginate-substituted coatings) were characterized by zeta
7 potential, Dynamic light scattering, Size Exclusion Chromatography, Scanning electron microscopy, and
8 Atomic force microscopy. Peripheral blood mononuclear cells (hPBMCs) and fibroblasts were exposed
9 for 1, 3, 7 and 10 days with cytokine secretion, viability and cell morphology as observations.

10 The coatings showed an increased rugosity and exponential growth mode with increasing layers. A
11 dose/layer dependent IL-10 response was observed in hPBMCs, which was greater than EPS624 in
12 solution, and was stable over 7 days. Fibroblast culture revealed no toxicity or metabolic change.

13 The EPS624 polyelectrolyte coatings are cytocompatible, have immunoregulatory properties and may
14 be suitable for further investigation in biomedical engineering.

15 Introduction:

16 Bacterial exopolysaccharides (EPS) are polymeric sugars produced by bacteria that are either located
17 external to, or attached to, its outer membrane. EPS serve many functions for bacteria including
18 protection from environmental stressors ¹, as a reservoir of water or nutrition ², and, in medically
19 important bacteria, as an aid to pathogenicity ³. *Bifidobacterium longum* is a Gram-positive commensal
20 bacterium present in the human gut. *B. longum* is known to produce EPS, which are believed to aid
21 adhesion to the intestinal epithelium and survival in the presence of low pH (in the stomach), bile salts
22 and pancreatic enzymes, as well as being a mediator molecule in the dialogue between the bacterium
23 and the intestinal mucosa ⁴.

24 Bacterial exopolysaccharides in general display good biocompatibility, biodegradability and non-toxicity,
25 making them suitable candidates for biomedical engineering. The most widely used bacterial EPS in
26 biomedical applications include the use of cellulose ⁵ due to its excellent mechanical properties and high
27 water retention capabilities; alginate ⁶ due to the facile crosslinking potential; and xanthan gum due to
28 its excellent water solubility, biocompatibility, immune inertness and positive viscoelastic properties ⁷.
29 Various bacterial EPS have been used for bone regeneration ⁸, rheological enhancement, drug delivery
30 and tissue engineering ⁹ as well as in wound healing ⁵ and osteoarthritis ⁷.

31 In many cases, the EPS may serve as a rather inert, biocompatible component in a composite
32 biomaterial that may be loaded with other active agents. However, a small number of EPS structures
33 have been shown to retain independent biological activity. For example, EPS from a *Bacillus circulans*
34 ¹⁰ and a *Bacillus Amyloliquefaciens* ¹¹, showed general and COX-2 specific anti-inflammatory properties,
35 which were hypothesized to be related to cell membrane stabilization, which was tested for red blood
36 cells in vitro, and proteinase inhibition ¹⁰ and nitric oxide inhibition ¹¹. Another EPS from a *Lactobacillus*
37 *paraplantarum* has been shown to reduce inflammatory cytokines and hyperalgesia in rats, linked to
38 increased IL-10 and IL-6 induction ¹². Another polysaccharide of interest is the EPS624 from
39 *Bifidobacterium Longum subsp. Longum 35624*, which has confirmed immunoregulatory properties.
40 EPS624 has been shown to increase IL-10 secretion and regulatory T cell recruitment in a number of
41 animal models or allergic airway diseases ¹³⁻¹⁵. The IL-10 induction was shown to follow a TLR-2
42 dependent pathway ¹⁶. More recently it was shown that EPS624 could prevent osteoclast maturation
43 under homeostatic and tumor necrosis factor alpha (TNF- α) induced inflammatory conditions ¹⁶,
44 suggesting it may have bone protective effects. However, when the EPS-producing *Bifidobacterium*
45 *35624* strain was administered orally in mice, it was only partially effective at preventing ovariectomy
46 induced bone loss, suggesting limitations of oral administration of EPS624 to achieve biological activity
47 in the bone. To overcome this potential loss in activity due to oral ingestion, local application of EPS624
48 directly to the bone could potentially be a beneficial approach to improve bone-targeted activity.

49 Polyelectrolyte coatings are an effective method to combine positively and negatively charged polymers,
50 creating multilayered coatings that may easily be loaded with hydrophilic molecules ¹⁷. Since they do
51 not require reactive molecular bonds, polyelectrolyte coatings retain the biological activity of their
52 constituent components to a larger degree than chemical immobilization methods ¹⁸. Furthermore, by
53 adjusting the number of layers, the amount of material on the surface and the subsequent release
54 kinetics may be influenced. Polyelectrolyte coatings from natural polymers have been used for a variety

55 of applications including blood-compatible chitosan/heparin coatings to reduce coagulation at the
56 implant surface due to their cytophilic and anticoagulant properties ¹⁹, increased biocompatibility for
57 orthopedic and dental implants, when using chitosan and heparin ²⁰, anti-microbial activity ^{21, 22}, for
58 example in a hyaluronic acid/polyarginine system ²², and drug delivery such as loading tamoxifen, which
59 is an anti-cancer drug, into chitosan/alginate films . A polyarginine/hyaluronic acid polyelectrolyte system
60 also reduced the innate immune response in a two-step granuloma formation model ²³.

61 Polyelectrolyte coatings composed of immunoregulatory bacterial EPS have not been previously
62 described. Therefore, the aim of this study was to prepare and characterize immunomodulatory
63 polyelectrolyte coatings using the negatively charged EPS624 with positively charged chitosan. In
64 particular, we characterize the physico-chemical properties of the polymers used in the polyelectrolyte
65 coating process, as well as the polyelectrolyte coatings surfaces themselves by scanning electron
66 microscopy and atomic force microscopy. In addition, we investigated the cytokine response of human
67 PBMCs and fibroblast cytotoxicity when exposed to solubilized EPS624 and polyelectrolyte coatings
68 containing EPS624. Our hypothesis is that EPS624 polyelectrolyte coatings can be constructed and
69 retain immunoregulatory activity, measured by induction of IL-10 secretion from exposed cells.

70 **Materials and methods:**

71 EPS624 production and purification

72 *Bacterial culture*

73 *Bifidobacterium Longum subsp. Longum 35624* (NCIMB 41003 (35624TM)) was acquired from NCIMB
74 Ltd (Aberdeen, UK) and stored in 20% glycerol stocks at -80°C.

75 Production and purification of EPS624 was performed based on a previously described protocol ^{13, 24}.
76 Briefly, the bacteria were first grown in de Man Rogosa and Sharpe Medium (MRS Broth; Sigma; St.
77 Louis, MO, USA) supplemented with 0.05% L-cysteine-HCl (L-Cysteine-HCl, Sigma; St. Louis, MO,
78 USA) and 3% glucose (D-Glucose, Sigma; St. Louis, MO, USA), at 37°C under anaerobic conditions
79 (GasPak EZ Anaerobe Container System, Becton Dickinson, Franklin Lakes, USA) for 72h. The culture
80 was then transferred to modified MRS agar (MRSA) plates. MRSA (per liter) was composed of:
81 Bacteriological Agar 15g, 10g peptone from casein, 2.5g yeast extract, 3g tryptose, 3g K₂HPO₄, 3g
82 KH₂PO₄, 3g Ammonium Citrate Tribasic, 0.2g sodium pyruvate, 1mL Tween 80, 0.575g MgSO₄*7H₂O,
83 0.12g MnSO₄*4H₂O, 0.034g FeSO₄*7H₂O (purchased from Sigma; St. Louis, MO, USA) originally
84 inspired from this patent. Cultures were grown under anaerobic conditions at 37°C for 3-5 days.

85

86 *EPS purification*

87 Bacterial colonies were collected using a cell scraper and resuspended in phosphate buffered saline
88 (PBS; Sigma; St. Louis, MO, USA) + 1 µg/ml RibonucleaseA (Sigma; St. Louis, MO, USA) + 5 µg/ml
89 Deoxyribonuclease I (Sigma; St. Louis, MO, USA) in sterile 50mL tubes. The tubes were shaken
90 manually to resuspend the EPS, and then agitated for 2h on a shaking plate at 4°C. The bacteria were
91 then removed by centrifuging the tubes at 20'000g for 30min at 4°C, and the supernatant filtered using
92 0.45 µm filters (TPP, Trasadingen, Switzerland).

93 The NaCl concentration of the EPS-containing supernatant was adjusted to 0.45M using saturated NaCl
94 solution. The EPS was then precipitated by addition of 3 times its volume of 100% ethanol at 4°C under
95 gentle manual stirring for 30s, before being stored for 2h at 4°C. The precipitate was then collected and
96 resuspended in MilliQ™ water. The resuspended liquid was transferred in a 12-14 kDa dialysis
97 membrane (Thermo Scientific, Waltham, Massachusetts, USA) and dialyzed for 3 days in MilliQ™ water
98 at 4°C on an agitating plate, with 3 water changes per day. The dialyzed liquid was then purified by
99 passing twice through reverse phase column chromatography, using SPE C18 columns Chromabond
100 (CarlRoth; Karlsruhe, Germany) with a HyperSep-96™ vacuum manifold (Thermo Scientific, Waltham,
101 Massachusetts, USA). Finally, the solution was filtered through 0.45um filters before being freeze dried
102 over 4 days using a Christ Alpha2-4LD Plus (Martin Christ, Osterode am Harz, Germany). Dried EPS
103 powders were stored at -80°C.

104

105 *Polyelectrolyte coating*

106 Polyelectrolyte coatings were composed from the EPS624 prepared as described above, chitosan with
107 a 75-85% degree of deacetylation and an average molecular weight (Mw) between 190.000 and 310.000
108 Da (Sigma; St. Louis, MO, USA) and alginic acid (Acros Organic; Geel, Belgium). The coating substrates
109 were 15mm diameter glass cover-slip disks (Biosystems; Muttenz, Switzerland). Glass disk holders were
110 printed with commercial PLA (DIM3NSIONS GmbH; Aesch; Switzerland) on an Ultimaker 3 machine
111 (Ultimaker; Utrecht; Netherlands). The coating protocol is shown in Fig. 1. MilliQ™ water was used for
112 all solutions. The pH of the polyelectrolyte and rinsing solutions were adjusted using acetic acid and
113 sodium hydroxide as appropriate. First, the glass disks were cleaned in 10mM sodium dodecyl sulfate
114 (SDS), then 0.1M hydrochloric acid, then MilliQ™ water. For both EPS624 and chitosan polyelectrolyte
115 baths, the concentration was 1mg/mL at pH 5 in MilliQ™, and the rinsing baths were MilliQ™ at pH 5.
116 For control coatings (with alginate instead of EPS624), the alginate polyelectrolyte bath was 1mg/mL,
117 pH 3 in MilliQ™, and the two following rinsing baths were MilliQ™ at pH 3. The cycle of dipping and
118 rinsing was repeated 1, 5 or 10 times. At the end of the process the discs were rinsed in MilliQ™ water
119 and dried at room temperature. The coating groups prepared were: uncoated glass disks, glass disks
120 with 1, 5 and 10 layers of chitosan and EPS624 (1, 5 and 10) and finally glass disks with 10 layers of
121 chitosan and alginate (10A). Specifically for the atomic force microscopy measurements, we included
122 more chitosan/EPS624 coatings with different numbers of double layers being 1, 3, 5, 8, 10, 13, 15, 18
123 and 20.




Figure 1: Scheme of the glass disk cleaning process and chitosan/EPS624 polyelectrolyte coating preparation process. Image prepared using Biorender®.

124

125

126

127

128 Characterization of EPS624

129 *Titration Curve*

130 Titration curves were made for 1mL of EPS624 by using hydrochloric acid and sodium hydroxide to
 131 control the pH of the solutions from 2.2 to 12.0.

132 *Size Exclusion Chromatography (SEC)*

133 The molecular characterization of EPS624 and chitosan was performed using a multi-detector size
 134 exclusion chromatography system. After solubilization, each sample was filtered through 0.45 μm nylon
 135 filters. The multi-detector SEC system used two on-line detectors: 1) multi-angle laser light scattering
 136 (MALS); 2) differential refractometer (DRI) as concentration detector. The molecular characterization
 137 allowed the determination of average molecular weights M_n , M_w and M_z , molecular weight distributions
 138 (MWD), macromolecule size and conformation. The MWD of EPS624 samples was obtained by a
 139 modular SEC system consisting of an Alliance 2695 separation module from Waters (Milford,
 140 Massachusetts, USA) equipped with two on-line detectors: i) MALS Dawn DSP-F photometer (Wyatt;
 141 Santa Barbara, California, USA); ii) 2414 differential refractometer (DRI) (Waters, USA) as concentration
 142 detector. Setup of the multi-detector SEC system was serial in the following order: Alliance-MALS-
 143 DRI.MALS detector uses a vertically polarized He-Ne laser, $\lambda=632.8$ nm, and simultaneously measures
 144 the intensity of the scattered light at 18 fixed angular locations ranging in the aqueous solvent from 14.5°
 145 to 158.3°. MALS detector coupled to a concentration detector allows to obtain the true molecular weight
 146 M and the size, i.e., the root mean square radius $\langle s^2 \rangle^{1/2}$ in short to hereafter denoted as radius of
 147 gyration R_g , of each fraction of the eluting polymer.

148

149 Characterization of polyelectrolyte solutions

150

151 *Zeta Potential*

152 A Zetasizer Nano S series (Malvern Panalytical, Malvern, UK) was used to measure the zeta potential
153 of the polysaccharides. Medium MW chitosan (Sigma; St. Louis, MO, USA) was dissolved in MilliQ™
154 water with 0.001M NaCl and 0.025M acetic acid at a concentration of 1mg/mL. Alginate (Acros Organic;
155 Geel, Belgium) was dissolved at concentration of 1mg/mL in MilliQ™ water with 0.001M NaCl. EPS624
156 was dissolved at a concentration of 1mg/mL in 0.001M NaCl in MilliQ™ water. The pH of the solutions
157 was adjusted to the desired values using acetic acid and sodium hydroxide. The measurements were
158 made using a folded capillary zeta cell (Malvern Panalytical; Malvern, United-Kingdom) and were
159 repeated 3 times for each group.

160 *Dynamic light scattering (Rg)*

161 A Zetasizer Nano S series (Malvern Panalytical; Malvern, United-Kingdom) was used for dynamic light
162 scattering measurements to determine the average particle diameter of the polymeric chains of EPS624,
163 alginate and chitosan in solution. Medium MW chitosan was dissolved in MilliQ™ water and 0.025M
164 acetic acid at a concentration of 1mg/mL. Alginate was dissolved at concentration of 1mg/mL in MilliQ™
165 water. EPS624 was dissolved at a concentration of 1mg/mL in MilliQ™ water. The solutions were then
166 diluted to 0.1mg/mL and 0.01mg/mL using the same specific individual dissolving solutions described
167 above. For chitosan, the pH was adjusted to 5 using sodium hydroxide. The measurements were made
168 using square polystyrene cuvettes (Malvern Panalytical; Malvern, United-Kingdom). Three different
169 samples were used for each group.

170 Dry polyelectrolyte characterization

171 *Scanning electron microscopy (SEM)*

172 Scanning Electron microscope observations were conducted using a field emission Hitachi S-4700 II
173 microscope (Hitachi Ltd, Tokyo, Japan) and a Quartz PCI image management system. After coating
174 preparation on glass disks, the coatings were left to dry at room temperature, without any ethanol
175 dehydration. The samples were sputter coated using gold palladium with a BAL-TEC MED 020 sputter
176 coater connected to a BALTEC MCS 010 and a BAL-TEC QSG 060 (BAL-TEC AG, FL). Micrographs
177 were taken with a working distance of 12mm, an accelerating voltage of 3.0 kV and a current of 40 μ A.

178 *Atomic Force Microscopy (AFM)*

179 Topography, roughness, and thickness of the polyelectrolyte films were characterized by atomic force
180 microscopy using a JPK Nanowizard® 3 instrument.

181 To determine the thickness of polyelectrolyte coatings, we used the ability of AFM to perform
182 nanoscratching²⁵. Taking advantage of that method was only possible due to the high differences in
183 hardness between the soft polyelectrolyte films and the much harder glass disks they were deposited
184 on. This methodology is illustrated in Fig. 2. Grooves were created by scanning 0.4x3 μ m² areas using
185 a TipsNano DRP-IN-C diamond coated silicon cantilever with single crystal diamond tip having 25 nm
186 curvature radius. The cantilever sensitivity (34 nm/V) was calibrated by doing a force curve on a sapphire
187 sample while the spring constant (198 N/m) was estimated using the thermal noise method²⁶. Nano-
188 scratching were carried out in contact mode at 10 Hz line scanning rate and using 400 nN applied force
189 setpoint. These values were chosen in order to minimize the lips at the border of grooves as can be

190 seen in the Fig. 2A and to avoid damaging the substrate which was inspected after nano-scratching a
191 glass disk reference sample. For each polyelectrolyte film, two grooves were performed: the first one
192 consists of 20 scans and the second 40 scans. Just after grooving the polyelectrolyte film, the surface
193 is imaged with the same cantilever using the Quantitative Imaging (QI) multiparametric mode developed
194 by JPK Instruments which consists of high-speed acquisition of force-distance curve at each pixel image
195 as illustrated in Fig. 2C. From the extent force curves, for each image pixel, one can extract the contact
196 point ie. the height at which the cantilever just starts to touch the surface along with the slope in the
197 repulsive part characterizing the material elasticity as can be shown respectively in the Fig. 2C and 2D.
198 In order to estimate the polyelectrolyte film thickness, this one must be completely removed from the
199 grooves by nano-scratching. This point is first validated by checking that the measured slope of extent
200 force curve at these locations corresponds to the one measured (200 N/m) on the glass reference
201 sample as illustrated in the Fig. 2D showing the height and slope profiles extracted from the Fig. 2A and
202 2B. The removing of the film is also confirmed by checking that the depth of the groove with 20 scans
203 (the left one in the Fig. 2A) is equivalent to the one measure with twice the number of scans (the right
204 one in the Fig. 2A). The film thickness is afterwards evaluated from the contact point height map
205 subtracting the mean height value of the film measured on areas at each sides of the grooves from the
206 mean height measured in the grooves as illustrated in the Fig. 2A. This measurement was carried out
207 after a preliminary linear background plane correction of the contact point height map.

208 Morphologies of the polyelectrolyte films were characterized using a biosphere B20-NCH
209 cantilever with resonance frequency of 330 kHz and spring constant of 40 N/m operated in dynamic
210 intermittent contact mode. The cantilever had a spherical tip with 20 nm diameter. Small topographic
211 features of the films were examined scanning $1 \times 1 \mu\text{m}^2$ areas with 512x512 pixel rate.

212




Figure 2: Protocol used to evaluate the thickness of polyelectrolyte films by nano-scratching with an atomic force microscope. The example is taken for the polyelectrolyte film consisting of 15 deposited monolayers. Two grooves were machined by scanning $0.3 \times 4 \mu\text{m}^2$ areas using a cantilever with single crystal diamond tip. The groove on the left in figure A) and B) corresponds to 20 consecutive scans while the one on the right corresponds to 40 scans. A) and B) represent the contact point height and slope mapping of force curves obtained after nano-scratching using the JPK Instrument Quantitative Imaging mode. An example of such force-distance curve corresponding to the blue circle location in figures A) and B) is presented in figure C) showing how slope and contact point height values are determined. Profiles of these two parameters corresponding to the grey and black arrows are presented in the figure D) where the blue dotted line corresponds to the value of force curve slope measured on a glass reference sample. The film thickness is evaluated by subtracting the mean height values obtained measured on polyelectrolyte film areas with the mean heights obtained in the two nano-scratched grooves. These areas are represented by white squares in the figure A).

213

214 **Biological assays**

215 *Viability of human fibroblasts exposed to polyelectrolyte coatings and EPS624 in solution*

216 Telomerase-immortalized human foreskin fibroblasts (hTERT-BJ1) were used to test the
 217 biocompatibility of the chitosan/EPS624 and chitosan/alginate coated cover slips. hTERT-BJ1 were
 218 purchased from Clontech (USA) and were routinely cultured as previously described²⁷. Briefly, hTERT-
 219 BJ1 were cultivated in alpha- Minimum Essential Medium (α -MEM) (Gibco™, ThermoFisher Scientific,
 220 USA) supplemented with 10 % fetal bovine serum (Corning, USA) with the addition of 100 $\mu\text{g}/\text{mL}$
 221 streptomycin (Gibco™, ThermoFisher Scientific, USA), 100 U/mL penicillin (Gibco™, ThermoFisher
 222 Scientific, USA) at 37 °C in a humidified 5% CO₂ atmosphere. Polyelectrolyte coated cover slips were

223 first placed in a 24-well plate and afterwards 5×10^3 cells per well were seeded on top of the cover slip.
224 The conditions tested included: 1, 5 and 10 layers of chitosan/EPS624, as well as 10 layers of
225 chitosan/alginate (10A). Non-coated cover slips were used as positive control. In addition, cells were
226 exposed to EPS624 dissolved in media at 1, 10 and 100 $\mu\text{g}/\text{ml}$. Cells were seeded in the well and the
227 EPS624 solutions were applied the following day. As positive control, cells were grown in complete
228 medium (α -MEM, 10% FBS and 1% P/S) without any EPS or coated cover slip. Cells treated with
229 dimethyl sulfoxide (DMSO, Sigma-Aldrich, USA) were used as negative control.

230 To determine cell viability, CellTiter-Blue® (Promega, USA) was used at day 1, 3, 7 and 10 following the
231 manufacturer's instructions. Cell viability (calculated in %) was determined as the fluorescence ratio
232 between cells grown on EPS624 coated cover slips and non-coated cover slips for the coating assay,
233 or cells exposed to the different concentrations of EPS624 and the positive control for the EPS624
234 dissolution in media assay. At each time point, cells were detached from the single well/coverslip and
235 counted using an automatic cell counting device fluidlabR300 (Anvajo, Dresden, Germany). The
236 average values and standard deviations were calculated from 3 replicates.

237 *Human peripheral blood mononuclear cells (hPBMC) isolation from buffy coat*

238 The hPBMCs used for the *in vitro* experiments were isolated from buffy coats provided by the Regional
239 Blood Donation Service SRK Graübunden (Chur, Switzerland). The blood was diluted in PBS and
240 carefully added to histopaque solution (Sigma; St. Louis, MO, USA) before being centrifuged at 800 rcf
241 for 30min. The cell pellet was taken from the solution using a Pasteur pipette, resuspended in Roswell
242 Park Memorial Institute (RPMI) media (RPMI Medium 1640, Gibco™, ThermoFisher Scientific, USA)
243 and then centrifuged 10 min at 300 rcf and room temperature. The supernatant was removed, fresh
244 media was added and the cells were centrifuged at 300 rpm for 10 min. After supernatant removal and
245 dilution to the appropriate concentration, the cells were stored in a 50% RPMI, 40% FBS (Corning, USA),
246 10% DMSO solution, at 5×10^6 cells/mL in liquid nitrogen. All experiments, except the final TNF- α ELISA,
247 were performed using the same buffy coat. A second buffy coat, from a second donor, was required for
248 the final experiment.

249 *hPBMC culture and exposure to polyelectrolyte coatings/EPS624 in solution*

250 hPBMCs were thawed from liquid nitrogen then cultured in RPMI media + 10%FBS (Corning) + 1% P/S
251 for 24h at 37°C before being counted and diluted to a concentration of 500.000 cells/mL in RPMI + 10%
252 FBS + 1% P/S for all experiments.

253 For experiments with EPS624 in solution the cells were cultured in 96 well plates, using 250 μL of media
254 per well and EPS624 concentrations of 1, 10 and 100 $\mu\text{g}/\text{mL}$. For experiments with EPS624
255 polyelectrolyte coatings, the coated glass disks were first deposited at the bottom of 24 well plates and
256 then 1mL of the RPMI media containing cells was added on top of each well.

257 In all cases, the cells were incubated for 24h at 37°C, after which the media in each well was centrifuged
258 for 5 min at 350rcf. The supernatants were then collected in Eppendorf tubes and stored at -20°C. The
259 experiment was repeated 4 times in total, with n=2 to 3 for each condition per assay.

260 *Coating stability assay*

261 Each disk was immersed in 5mL of sterile PBS in a sterile glass vial. The glass vials were placed in a
262 37°C incubator with 100 rpm agitation for 1, 3 or 7 days to allow release of EPS624 into the solution. At
263 the end of the immersion period, each disk was rinsed in MilliQ™ water and dried at room temperature.
264 The uncoated glass control group with no PBS immersion was also rinsed in MilliQ™ water and dried at
265 room temperature. The disks were later used for the PBMCs experiments as described previously. The
266 groups tested included chitosan/EPS624 coatings containing 1, 5 and 10 layers of each polymer, with
267 all groups tested after 0, 1, 3 and 7 days immersion.

268 *Cytokine measurements*

269 Secreted Interleukin (IL-10) and Tumor Necrosis Factor (TNF- α) were measured in supernatants of the
270 hPBMCs cultures using a human IL-10 Duoset ELISA (reference DY217B) and a human TNF- α Duoset
271 ELISA (reference DY210) from R&D Systems (R&D Systems, Minneapolis, USA). A wider range of
272 secreted pro and anti-inflammatory cytokines were measured using A U-PLEX T cell combo (hu) sector
273 multikit (reference K15093, Mesoscale, Rockville, USA), that included the following markers: TNF- α ,
274 IFN- γ , GM-CSF, MIP-3 α , IL-2, IL-4, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL17E-25, IL-21 and IL-22.


275 Statistics

276 GraphPad Prism 9 was used for all statistical analyzes. ELISA IL-10, and U-plex T cell combo (hu)
277 experiments were repeated 3 times, with N=2 to 3 per condition for each singular experiment and the
278 datasets used for statistical analysis combine all individual values from each of the triplicate
279 experiments. For all experiments, each group from each dataset was tested for normal distribution with
280 the following tests: Anderson-Darling test, D'Agostino and Pearson test, Shapiro-Wilk test, Kolmogorov-
281 Smirnov test. If one group from a dataset did not pass the normal distribution on one of these 4 tests,
282 then the dataset was considered as not normally distributed. According to this criteria, all dataset were
283 not normally distributed, so a non-parametric Dunn's multiple comparison test was used to determine
284 statistical differences between the groups of each dataset. Statistical significance is displayed as follows:
285 ns or an absence of sign for no statistical difference, * for $p < 0.05$, ** for $p < 0.01$, *** for $p < 0.001$, **** for
286 $p < 0.0001$.

287 **Results & Discussion**

288 EPS624 characterization:

289 The titration curve of the EPS624 is shown in Fig. 3A. An equivalence point is observed at a pH of 6.73.
290 Quantifying the pH at half the volume of equivalence, a pKa of 2.45 is obtained, indicating that the
291 EPS624 fraction purified is a rather weak acid.



292

293 Figure 3: A: Titration curve of the EPS624 at 1mg/mL, with measured pKa.; B: Overlay of differential refractometer
 294 (DRI) and multi-angle laser light scattering (MALS) signals for EPS624 with peak being described in text; C:
 295 Scanning Electron Microscopy Image of Bifidobacterium Longum subsp. Longum 35624 and the associated
 296 EPS624 when grown on modified MRS agar.

297 The elution fractions of the EPS624 measured by DRI and MALS 90° detectors is shown in Fig. 3B,
 298 while the elution fraction of the chitosan is represented in Supplementary Figure 2. The EPS624 fraction
 299 measured by DRI is represented by one single peak 1, while the peaks 2, 3 and 4 represent impurities
 300 that can be attributed to remaining solvents, salts or proteins. List of calculated EPS624 molecular
 301 weights and gyration radiuses are reported Table 1. Equivalent data for chitosan is shown in
 302 Supplementary Table 1 and 2. A high molecular weight Mw of 639.9kg/mol is calculated in the range,
 303 10 and 1000kg/mol, reported for other bacterial exopolysaccharides with a polydispersity of 1.9²⁸.The
 304 MALS 90° (LS 90) elution curve shows two subpeaks. As EPS624 analysis by MALS has not been
 305 reported previously further investigations will be required to assess the presence of aggregation and
 306 conformational properties of the branched polysaccharide.

307 Table 1: Molecular weights and radii of gyration of EPS624 as determined by SEC. Rgn corresponding to the
 308 number average radius of gyration, Rgw to the mass average radius of gyration and Rgz to the Z-average radius
 309 of gyration.

Mn kg/mol	Mw kg/mol	Mz kg/mol	Mw/Mn	Mz/Mw	Recovered Mass (%)	Rgn nm	Rgw nm	Rgz nm	K nm	α
339.9	639.9	955.6	1.90	1.49	77.3	62.7	92.4	118.6	0.0306	0.599

310

311 Figure 2C is a Scanning Electron Microscopy image of the Bifidobacterium Longum subsp. Longum and
 312 associated EPS624 when grown on agar plates. The EPS624 can be seen attached to the bacterial cell
 313 wall and in between each cell, forming a "spider-net" like structure when in a dehydrated state.


314 Overall, the EPS624 production process yield a polysaccharide with a recovery mass above 75% with
 315 remnants attributed to solvent, salts and potentially others proteins. This is of high relevance as the
 316 impurities might affect the biological properties of the EPS624 and chitosan/EPS624 polyelectrolyte
 317 coatings. Potential sources of impurities are the MRS broth used to grow the bacteria, or other bacterial
 318 components from the Bifidobacterium released during the centrifugation step, due to the extreme speed
 319 used which very likely destroys bacterial cell membranes. These components could potentially bind to
 320 some of the EPS624 functional groups and therefore be present in the final product.

321

322 Characterization of solutions used in polyelectrolyte coatings:

323 The average polymer particle diameters in solution for alginate, chitosan and EPS624 are shown in Fig.
 324 2B and Fig. 2C. At both 0.1 and 0.01 mg/mL, alginate has the highest average particle diameter, followed
 325 by chitosan, with the lowest being EPS624. For alginate in particular, an increase in the particle diameter
 326 is observed as concentration increases, suggesting a degree of aggregation with increased
 327 concentration³⁰, which was not apparent for chitosan or EPS624. EPS624 displayed the lowest variation
 328 in diameter, suggesting a lower polydispersity of the average particle size, consistent with SEC results,
 329 compared with chitosan and alginate, which respectively showed a higher polydispersity or aggregation
 330 as concentration increases.

331 The Zeta Potential of the alginate, chitosan and EPS624 at different pH values is shown in Figure 4A.
 332 Both EPS624 and alginate have negative Zeta potential at all pH tested, while chitosan Zeta potential is
 333 positive in the same range. Alginate Zeta potential values are lower than EPS64 Zeta potential at all
 334 tested pH values. Overall, a decrease in Zeta Potential is observed with increased pH for all polymers,
 335 which is in accordance with published literature for chitosan²⁹. The Zeta potential values indicates that
 336 EPS624 and chitosan in solution likely form polyelectrolyte complex like alginate and chitosan. Changes
 337 of polyelectrolyte baths pH and ionic strength influence solutions Zeta potential, increase colloidal
 338 stability and reduce the risk of aggregate formation prior to mixing. These also influence attractive forces
 339 between the positively charged and negatively charged polysaccharides when mixed and consequently
 340 the thicknesses and topographies of polyelectrolyte multilayer coatings as well as potential interactions
 341 will cells^{32, 33}. A previously reported protocol for the formation of chitosan and hyaluronic acid
 342 polyelectrolyte multilayer coatings was replicated for the production of EPS624/chitosan polyelectrolyte



344

345 *Figure 4: A: Evolution of measured Zeta potential of EPS624, alginate and chitosan at a concentration of 1mg/mL*
 346 *with pH; B: Average polymer particle diameter in solution at 0.1mg/mL as measured by dynamic light scattering; C:*
 347 *Average polymer particle diameter in solution at 0.01mg/mL as measured by dynamic light scattering*

348


349 Dry EPS624/Chitosan polyelectrolyte coatings thickness, topography and mechanical properties

350 *Atomic force microscopy*

351 The formation and evolution of the polyelectrolyte coating with increasing number of layers was followed
 352 by AFM (Fig. 5A). The coating thickness follows an exponential growth in the range of layers explored
 353 up to 70 nm for 20 chitosan/EPS624 multilayer coating. The surface morphologies of polyelectrolyte

354 coatings consisting of 1, 5 and 13 double layers are shown in Fig. 5C D and E. The surface morphology
355 of a monolayer predominantly exhibits a small structural feature reminiscent of phase-separated
356 polymers with blisters of less than 50 nm. These blisters grow in size and number, and finally cover the
357 entire surface-giving rise to a globular texture with objects of diameters up to 150 nm in the case of 13
358 double layers sample. The thickness exponential growth together with the globular objects of growing
359 diameters are concurrent in supporting a mechanism of chitosan/EPS624 multilayers formation based
360 on the diffusion through the film of one of the polysaccharide “in” and “out” during build-up has been
361 described for polylysine/hyaluronan polyelectrolytes ³⁴. Meanwhile, the roughness values present a
362 linear correlation with the number of layers (Fig. 5B). Since the nanoscale topographies affect cell
363 behaviors ³⁷, we might hypothesize that the number of layers could change cellular response not only
364 based on the amount of material contained in the coating, but also in the topological and mechanical
365 cues given to the cells ³⁸.

366 Previous research has shown that the differences between dry and wet polyelectrolyte coating
367 thicknesses are heavily dependent on the system used, with for example a thickness increase of only a
368 few percent in a chitosan/chondroitin sulfate system but higher than 90 percent in a chitosan/hyaluronic
369 acid system ³⁵. Measurements of the levels of hydration of polyelectrolyte coatings in situ also show
370 large differences based on the system used, being for example 76% for poly(L-lysine)/Hyaluronic acid
371 coatings, 63% for poly(L-lysine)/Chondroitin sulfate A coatings and 20% for poly(L-lysine)/Heparin
372 coatings ³⁶.
373




374 Figure 5 : A) evolution of polyelectrolyte film thickness determined by the nano-scratching method presented in
375 the Fig. 2 and B) roughness (arithmetical mean height) in function of the number of layers deposited during the film
376 elaboration protocol. The film structuring with the number of deposited layers is highlighted by intermittent contact
377 AFM imaging in the figures C), D) and E) showing respectively the surface morphologies of 1, 5 and 13 monolayers
378 deposited films.

379

380 Scanning Electron Microscopy (SEM)

381 Polyelectrolyte coatings observed by Scanning Electron Microscopy are shown in Fig. 6, with noticeable
382 differences between the groups. The clean uncoated glass disc, used as substrate material for the
383 coatings, shows a very smooth surface with no apparent rugosity or irregular topography. When looking
384 at the chitosan/EPS624 groups, noticeable changes in topography are observed as the number of layers
385 increases. In the 1 layer group, polysaccharide deposition on top of the glass surface is visible. While
386 an overall smooth surface is observed, several deposits of presumptive polysaccharides, with width
387 ranging from 30nm to 300nm, can be observed everywhere on the surface. As the number of layers
388 increases to 5 and then 10, an increase in the overall rugosity of the surface as well as an increase in
389 density of these particular deposits are seen. In comparison, the 10 layers alginate group shows an
390 overall much smoother topography with fewer particular deposits. We hypothesized the presence of
391 these particular deposits and change in rugosity were the results of the attachment of EPS624 or
392 chitosan particles as the width of these particles were compatible with the particle diameter measured
393 by dynamic light scattering (Figure 4B and 4C). However, we think this change in topography and
394 rugosity is most likely due to the exponential growth of the coatings that was previously discussed in the
395 atomic force microscopy section, as polyelectrolyte coatings with evolving topographies were already
396 observed in other systems ³².




397

398 Figure 6: Images of EPS624/Chitosan and Alginate/Chitosan polyelectrolyte coatings by Scanning Electron
399 Microscopy

400

401 Cell viability of human fibroblast after exposure to EPS624 and growth on polyelectrolyte coatings

402 The influence of EPS624 in solution on human fibroblast metabolic activity were tested after 1, 3, 7 and
 403 10 days. Cells exposed to 1, 10 or 100 $\mu\text{g/ml}$ of EPS624 show no changes in metabolic activity over 7
 404 days with values comparable between these 3 conditions and the positive control (Figure 7 A). However,
 405 the cell count trended downwards with increasing EPS624 concentration at day 1 (Figure 7 B). On day
 406 3, all the conditions are in the range of $\sim 6 \times 10^4$ cells, while a net increase is measured at day 7 ($\sim 2.3 \times 10^5$
 407 cells). However, when normalizing the metabolic activity to the cell number, it appears as a general trend
 408 that a lower cell number corresponds with a higher metabolic activity (Supplementary Fig. 3A). This
 409 trend is higher for EPS 100 $\mu\text{g/ml}$ and EPS 10 $\mu\text{g/ml}$ compared to EPS 1 $\mu\text{g/ml}$ and the positive control
 410 on day 1 and day 3. We can hypothesize that due to the attachment of an absolute lower number of
 411 cells, the lower cell density requires a higher need for proliferation before reaching confluency, which
 412 could lead to a higher individual cell metabolic rate. Another possibility is a direct effect on cell
 413 proliferation rate ³⁹, as EPS-A28, another bacterial exopolysaccharide from *Alteromonas* PRIM-28 was
 414 shown to increase dermal fibroblasts proliferation by increasing cell activity during the S-phase cycle
 415 and expression of fibroblast Ki-67 proliferation marker ⁴⁰.



416

417


418

419 Figure 7: A: Human fibroblast hTERT-BJ1 exposed to EPS624 for 1, 3 and 7 days. A. Cell metabolic activity of
 420 hTERT-BJ1 exposed to 1, 10 or 100 $\mu\text{g/ml}$ of EPS624 in complete medium (α -MEM, 10% FBS, 1% P/S). Cell
 421 metabolic activity is shown in % and was determined as the fluorescence ratio between cells exposed to EPS624
 422 and positive control (cells in complete medium). Dashed line represents the positive control, 100 %. **B. Cell count**
 423 of hTERT-BJ1 exposed to 1, 10 or 100 $\mu\text{g/ml}$ of EPS624 in complete medium (α -MEM, 10% FBS, 1% P/S). At every
 424 time point, cells were detached from the single well and counted. Dashed lines represent the mean of the positive
 425 controls at each time point.

426

427 The various EPS624/chitosan polyelectrolyte coated cover slips were also exposed to human fibroblast
428 to evaluate cell attachment, proliferation, and metabolic activity over 10 days (Figure 8). While not
429 significant, cell metabolic activity at day 1 and day 3 shows a trend of lower activity for 5 and 10 layers
430 compared to 1 layer and to the positive control (Figure 8, A). For all days, we observe the
431 chitosan/alginate coatings (10A) have the lowest metabolic activity out of all the groups. In contrast to
432 observations in the case of the EPS624 in solution, the lower metabolic activity correlates with the lower
433 cell number (Figure 8 B).

434 Additionally, cell attachment and proliferation on the polyelectrolyte coated cover slips appears strongly
435 influenced by the number of chitosan/EPS624 layers when observed through microscopy
436 (Supplementary. Fig. 1). The 5 layers and 10 layers groups induce a more aligned organization of the
437 cells, compared with the more commonly observed random and more disperse cell attachment. The
438 differences in cell attachment, proliferation and organization are most likely due to the evolving surface
439 properties of the polyelectrolyte coatings as the number of layers increases. According to the Wenzel
440 model, an increase in surface roughness can increase the hydrophobicity of hydrophobic surfaces, as
441 well as increase the hydrophilicity of hydrophilic surfaces ⁴¹. The hydrophilicity and hydrophobicity of a
442 surface largely determines protein adsorption and protein denaturation, which in turn influence
443 subsequent cell behavior ⁴². Changes in roughness, that were observed by atomic force microscopy,
444 have previously been shown to affect cell adsorption and migration ⁴³, and it was observed that a
445 moderately hydrophilic surface with a contact angle of around 70° led to the best fibroblast proliferation
446 ⁴⁴. In addition, topographical structures, such as the presence of grooves and ridges can also influence
447 protein adsorption and promote cells to align in the direction of the grooves and ridges ⁴⁵. As observed
448 with the SEM and AFM data, we see an increase in surface roughness as the number of layers
449 increases, and the AFM data shows an evolution of the topographic profile of the coatings as the number
450 of layers increases. These two parameters could explain the initial difference in cell attachment, as well
451 as the aligned orientation of the cells in the groups with more layers. Surface compliance is another
452 element playing a role in cell behavior, with cells generally attaching and migrating more on stiffer/harder
453 surfaces ⁴⁶. Due to the very thin nature of the coatings, we can hypothesize that the stiffness that the
454 cell can "feel" would be higher for the coatings with lower numbers of layers, as the distance with the
455 glass substrate is very small and it can probably still be felt, while this effect gets lower as the thickness
456 of the polyelectrolyte coating increases, where the cell predominantly feel the properties of the
457 polyelectrolyte coating. This could explain a lower attachment for groups with a higher number of
458 coatings. A final potential reason for this observation is the changing of the surface charge of the coating
459 as the number of layer increases. With the exponential growth of the coatings shown in Fig. 5A, we can
460 hypothesize that higher amounts of EPS624 are present at the surface sensed by the cells, potentially
461 changing the surface charges that can also influence protein adsorption and, therefore, cell behavior.
462 While we initially see a lower adhesion for the 5 layers and 10 layers groups, the cells attach in a more
463 aligned manner and are able to grow, and there is no difference in cell number and metabolic activity at
464 day 10, showing all coatings are adequate surfaces for fibroblast growth.



465

466

467

468 Figure 8: A: Human fibroblast hTERT-BJ1 grown on EPS624 coated coverslips for 1, 3, 7 and 10 days. A. Cell
 469 metabolic activity of hTERT-BJ1 grown on the different cover slips functionalized with either 1, 5 or 10 layers of
 470 EPS624 and chitosan (1, 5 and 10) or 10 layers of alginate and chitosan (10A). Cell metabolic activity is shown in
 471 % and was determined as the fluorescence ratio between cells grown on functionalized cover slip and positive
 472 control (cells on non-functionalized cover slips). Dashed line represents the positive control, 100 %. B. Cell count
 473 of hTERT-BJ1 grown on the different cover slips functionalized with either 1, 5 or 10 layers of EPS624 and chitosan
 474 (1, 5 and 10) and 10 layers of alginate and chitosan (10A). At every time point cells were detached from the single
 475 well and counted. Dashed lines represent the mean of the positive controls at each time point. The average values
 476 and standard deviations were calculated from 3 parallel samples.

477

478 Bacterial adhesion on polyelectrolyte coatings

479 *Staphylococcus aureus* adhesion to the polyelectrolyte coatings was assessed for 24h and 4 days, with
 480 methods and results shown in Supplementary Figure 4. Overall, the number of layers per coatings did
 481 not affect bacterial adhesion significantly, however the adhesion was increased in the coated cover slips
 482 compared to the uncoated cover slips. While the number of polyelectrolyte coatings layers affect
 483 fibroblast adhesion, it seems that *S. aureus* adhesion is not affected. Inactivated *L. casei* biofilms were
 484 shown to have anti-bacterial activity on methicillin resistant *S. aureus* in the literature, however it seems
 485 these effects were related to the presence of lactic acid and bacteriocin in the biofilm, and not the
 486 structure of the exopolysaccharide in contained ⁴⁷.

487 IL-10 secretion by hPBMCs:

488 IL-10 secretion was previously shown to be specifically induced by EPS624 in monocyte derived
489 dendritic cells ¹⁵ and osteoclasts precursor cells ¹⁶ and we investigated whether this IL-10 induction is
490 also present in hPBMCs when EPS624 was incorporated into polyelectrolyte coatings.

491 IL-10 secretion by hPBMCs after exposure to EPS624, either dissolved in media or incorporated in
492 polyelectrolyte coatings, is shown in Fig. 9A and Fig. 9B. When dissolved in media, a dose response
493 effect is observed with increase of IL-10 secretion when exposed to increasing concentrations of
494 EPS624 ($p < 0.05$). The concentration levels inducing an IL-10 response are coherent with what was
495 observed in osteoclast precursor cells where a concentration of 50 μ g/mL increased IL-10 secretion ¹⁶,
496 while in monocyte derived dendritic cells, a trend for increased IL-10 secretion was observed up to 200
497 μ g/mL concentrations ¹⁵. However, failure to further increase IL-10 levels after increasing from 10 μ g/mL
498 to 100 μ g/mL suggests an upper threshold is reached beyond which higher IL-10 secretion is not
499 achieved.



500

501 When looking at EPS624 incorporated in polyelectrolyte coating, a dose-dependent increase is also
502 observed as the number of layers in the EPS624 coatings increases. However, the 5 and the 10 layers
503 groups show no statistical difference suggesting a "saturation effect". The IL-10 response is of higher
504 magnitude in the chitosan/EPS624 polyelectrolyte coatings compared to the EPS624 dissolved in media
505 at 10 μ g/mL and 100 μ g/mL, however it does not reach statistical significance. One hypothesis for this
506 higher secretion is that despite a low total amount of EPS624 in the coating, which was estimated in
507 supplementary data and could theoretically lead to a maximal EPS624 concentration of 4.41 μ g/mL for
508 the 10 layers groups, and lower concentrations for the other groups, its direct contact to the cells on the
509 surface might lead to a higher exposure of the polymer to the cell receptors, therefore potentially
510 increasing IL-10 expression.

511

512 Another interesting observation is the much lower IL-10 secretion in the 10 layers chitosan/alginate
513 group compared to the 10 layers chitosan/EPS624 group ($p < 0.01$). This finding confirms the specificity
514 of the EPS624 for IL-10 secretion. Alginate is a well-known biomaterial with a good biocompatibility often
515 used for wound dressing, however it does not have the specific IL-10 secretion activity of the EPS624.
516 This property of EPS624 coatings may therefore, offer additional biologically advantageous properties
517 compared with conventional equivalents.

518




519
 520 *Figure 9: A: human peripheral blood mononuclear cell secretion of IL-10 when exposed to EPS624 dissolved in*
 521 *RPMI media for 24h, quantified by ELISA. Experiments were repeated 4 times with n=3 for each condition; B:*
 522 *human peripheral blood mononuclear cell secretion of IL-10 when exposed to EPS624/chitosan with different*
 523 *number of layers or alginate/chitosan with 10 layers (10A) polyelectrolyte coatings for 24h, quantified by ELISA.*
 524 *Experiments were repeated 4 times with n=2-3 for each condition, the total amount of sample N is between 10*
 525 *and 12 for each group*

526 Coating Stability:

527 To estimate the stability of the EPS624 coatings, they were stored in in PBS for 0, 1, 3 or 7 days and
 528 subsequently cultured with hPBMCs as represented in Figure 10. A reduction in IL-10 secretion was
 529 seen between the control groups (0 day) and the 1, 3 and 7 days groups, with often no statistically
 530 significant difference between day 1, 3 and 7. Higher secretions for the 5 and 10 layers groups compared
 531 to the 1 layer group are also observed.

532 The initial drop in IL-10 secretion between the control and the first day could be attributed to a fast
 533 release in the PBS of weakly bound polymer chains/particles during the first 24 hours. The subsequent
 534 constant IL-10 secretion thereafter suggests a relative resistance of the coating to degradation by
 535 hydrolysis. Another possibility for the main degradation mechanism of the coating is the dissolution of
 536 the polymer matrix rather than a scission of the polymer chains. This suggests that the coating could
 537 keep its activity for several days, and potentially longer. It can be hypothesized that with a higher number

538 of layers, a sufficient amount of EPS624 might be available to the cells for a longer time, potentially
 539 increasing the duration of biological activity. In vivo, oxidative reactive species can degrade
 540 polysaccharides which are actively transported by phagocytes⁴⁸. Our in vitro approach does not account
 541 for active biological degradation and chemically induced degradation with slow kinetics, and could be
 542 an area for further characterization of these coatings to estimate in vivo activity profile.
 543



544

545 *Figure 10: human peripheral blood mononuclear cells secretion of IL-10 when exposed for 24h to A: 1 layer, B: 5*
 546 *layers, C: 10 layers of EPS624/chitosan polyelectrolyte coatings after being soaked in PBS for various lengths of*
 547 *time, quantified by ELISA. Each graph combines the data of 4 different experiment with n=2-3 for each condition,*
 548 *the total amount of sample N is between 8 and 10 for each group*

549


550 Pro and anti-inflammatory cytokine secretion in vitro:

551 Subsequently, a larger panel of cytokines were analyzed from the hPBMC supernatants to provide a
 552 broader perspective on potential immune responses to the EPS624 coatings. Negligible concentrations
 553 are measured for IL-2, IL-4, IL-9, IL-13, IL-17F, IL17E/25, IL-21 and IL-22. The results for these, and all
 554 other tested analytes can be found in the Supplementary Fig.5 and Fig.6. IL-10 secretion in Fig. 6A and
 555 Fig. 6B, shows very similar trends to the one observed for the ELISA-IL10 secretion. These results
 556 suggest an IL-10 specific response following exposure to EPS624. TNF- α was also quantified as it is an
 557 important cytokine. It is produced during an acute inflammation phase. Its concentrations remain high
 558 in a chronic inflammation, but are decreasing in a normal anti-inflammatory healing process mediated
 559 notably by an IL-10 secretion.

560 Dissolved in media, EPS624 induce a TNF- α dose dependent response for concentrations above
 561 10mg/mL. On all coatings, higher TNF- α concentrations are measured in media for seeded and cultured
 562 hPBMCs (Fig. 11D). The high TNF- α secretion could be partially responsible for the IL-10 secretion
 563 measured. Interestingly, the 10 layers chitosan/alginate group induces a high TNF- α secretion indicating
 564 that EPS624 alone is not responsible for the observed increased. hPBMCs were then exposed to each
 565 of the polymeric reagents dissolved in media. Alginate shows low levels of TNF- α induction for all
 566 concentrations tested while chitosan shows a significant and strong dose dependent response
 567 (Supplementary Fig. 7). The chitosan effect on the TNF- α concentrations and pro or anti-inflammatory

568 response in vitro and in vivo have been reported elsewhere and are highly dependent on its molecular
569 weight, preparation method, as well as the previous stimuli to which the cells were exposed ^{49,50,51}.
570 EPS624 also shows a dose dependent TNF- α response caused either by endotoxin contamination, by
571 the presence of residual proteins and bacterial products in the tested batch or by inherent EPS624
572 activity, although the later has not been reported previously. Endotoxin tests, shown in Supplementary
573 Fig. 8, reveal the presence of low levels of endotoxin in the EPS624, chitosan and alginate used.
574 EPS624 has the highest level, followed by chitosan and alginate, however all concentrations are below
575 0.5EU/mL, regarded as an acceptable range by the FDA for implantation of human medical devices in
576 contact with the cardiovascular or lymphatic system ⁵². Therefore, it seems unlikely that endotoxin is a
577 major contributing factor to the observed TNF- α secretion. A more plausible hypothesis is that the TNF-
578 α secretion occurs due to the chitosan as the chitosan/alginate coating present the highest TNF- α
579 secretion, and the residual bacterial contaminants in EPS624. Improvements could be made in the
580 EPS624 production methods to further lower endotoxin and other contaminant levels, such as switching
581 from a broth to agar bacteria seeding to a glycerol stock to agar seeding, which could reduce the quantity
582 of potential contaminants contained in the broth to be purified later in the process. A chitosan with a
583 different molecular weight could also be an alternative to further modulate the TNF- α response and
584 subsequent biological response. For example, TNF- α at 5ng/mL combined with EPS624 was found to
585 prevent osteoclasts differentiation and activation ¹⁶. Additional in vivo experiments are required to
586 demonstrate the functionality of the EPS624/chitosan coatings.

587



588

589

590 *Figure 11: A: human peripheral blood mononuclear cells secretion of IL-10 when exposed to EPS624 dissolved in*
 591 *media at various concentrations for 24h, quantified by U-plex measurement; B: human peripheral blood*
 592 *mononuclear cells secretion of IL-10 when exposed to EPS624/chitosan with different number of layers or*
 593 *alginate/chitosan with 10 layers (10A) polyelectrolyte coatings for 24h, quantified by U-plex measurement; C:*
 594 *human peripheral blood mononuclear cells secretion of TNF-α when exposed to EPS624 dissolved in media at*
 595 *various concentrations for 24h, quantified by U-plex measurement; D: human peripheral blood mononuclear cells*
 596 *secretion of TNF-α when exposed to EPS624/chitosan with different number of layers or alginate/chitosan with*
 597 *10 layers (10A) polyelectrolyte coatings for 24h, quantified by U-plex measurement. For both TNF-α and IL-10*
 598 *measurement, for each group N=3 (each point being the average of an experiment), each experiment has n=3 for*
 599 *each condition*

600

601

602

603 **Conclusion:**

604

605

606

607

608

609

In this work polyelectrolyte multilayer coatings based on EPS624 and chitosan were successfully developed. The polyelectrolyte films showed an exponential growth with increased topography and rugosity. The coatings effectively stimulated a specific IL-10 secretion by hPBMCs reaching concentrations equivalent or higher to concentrations measured in presence of EPS624 solubilized in media. Additionally, the coatings remained functional for at least 7 days, inducing a significant IL-10

610 secretion. Pending further purification of the materials used, these coatings hold potential in instructing
611 pro-healing inflammatory conditions for local immunomodulatory applications.

612 Acknowledgements

613 We acknowledge Pamela Furlong for her help in the acquisition of the Scanning Electron Microscopy
614 images. We acknowledge Adeline Tronel for her help in Zeta Potential and Dynamic Light Scattering
615 measurements collection.

616 Funding

617 This work was funded by AO Trauma, grant number AR2018_04.

618

619 (1) Limoli, D. H.; Jones, C. J.; Wozniak, D. J. Bacterial Extracellular Polysaccharides in
620 Biofilm Formation and Function. *Microbiol Spectr* **2015**, 3 (3). DOI:

621 10.1128/microbiolspec.MB-0011-2014.

622 (2) Freitas, F.; Torres, C. A. V.; Reis, M. A. M. Engineering aspects of microbial
623 exopolysaccharide production. *Bioresour Technol* **2017**, 245 (Pt B), 1674-1683. DOI:

624 10.1016/j.biortech.2017.05.092.

625 (3) Klaus W. E. Rudolph, M. G., Firoos Ebrahim-Nesbat, Matthias Nöllenburg, Alim
626 Zomorodian, Kerstin Wydra, Michael Neugebauer, Ursula Hettwer, Wagih El-Shouny, Bernd
627 Sonnenberg & Zoltan Klement the role of extracellular polysaccharides as virulence factors
628 for phytopathogenic pseudomonads and xanthomonads. *Molecular mechanisms of bacterial*
629 *virulence* **1994**, 357-378.

630 (4) Castro-Bravo, N.; Wells, J. M.; Margolles, A.; Ruas-Madiedo, P. Interactions of Surface
631 Exopolysaccharides From Bifidobacterium and Lactobacillus Within the Intestinal
632 Environment. *Front Microbiol* **2018**, 9, 2426. DOI: 10.3389/fmicb.2018.02426.

633 (5) Qiu, Y.; Qiu, L.; Cui, J.; Wei, Q. Bacterial cellulose and bacterial cellulose-vaccarin
634 membranes for wound healing. *Mater Sci Eng C Mater Biol Appl* **2016**, 59, 303-309. DOI:
635 10.1016/j.msec.2015.10.016.

636 (6) Pourali, P.; Yahyaei, B. Wound healing property of a gel prepared by the combination of
637 Pseudomonas aeruginosa alginate and Alhagi maurorum aqueous extract in rats. *Dermatol*
638 *Ther* **2019**, 32 (1), e12779. DOI: 10.1111/dth.12779.

639 (7) Kumar, A.; Rao, K. M.; Han, S. S. Application of xanthan gum as polysaccharide in tissue
640 engineering: A review. *Carbohydr Polym* **2018**, 180, 128-144. DOI:
641 10.1016/j.carbpol.2017.10.009.

642 (8) Bagnol, R.; Grijpma, D.; Eglin, D.; Moriarty, T. F. The production and application of
643 bacterial exopolysaccharides as biomaterials for bone regeneration. *Carbohydr Polym* **2022**,
644 291, 119550. DOI: 10.1016/j.carbpol.2022.119550.

645 (9) Mohd Nadzir, M.; Nurhayati, R. W.; Idris, F. N.; Nguyen, M. H. Biomedical Applications of
646 Bacterial Exopolysaccharides: A Review. *Polymers (Basel)* **2021**, 13 (4). DOI:
647 10.3390/polym13040530.

648 (10) Vidhyalakshmi, R.; Valli, N. C.; Narendra Kumar, G.; Sunkar, S. Bacillus circulans
649 exopolysaccharide: Production, characterization and bioactivities. *Int J Biol Macromol* **2016**,
650 87, 405-414. DOI: 10.1016/j.ijbiomac.2016.02.001.

651 (11) El-Newary, S. A.; Ibrahim, A. Y.; Asker, M. S.; Mahmoud, M. G.; El Awady, M. E.
652 Production, characterization and biological activities of acidic exopolysaccharide from marine
653 Bacillus amyloliquefaciens 3MS 2017. *Asian Pac J Trop Med* **2017**, 10 (7), 652-662. DOI:
654 10.1016/j.apjtm.2017.07.005.

655 (12) Dinic, M.; Pecikoza, U.; Djokic, J.; Stepanovic-Petrovic, R.; Milenkovic, M.; Stevanovic,
656 M.; Filipovic, N.; Begovic, J.; Golic, N.; Lukic, J. Exopolysaccharide Produced by Probiotic
657 Strain Lactobacillus paraplantarum BGCG11 Reduces Inflammatory Hyperalgesia in Rats.
658 *Front Pharmacol* **2018**, 9, 1. DOI: 10.3389/fphar.2018.00001.

659 (13) Altmann, F.; Kosma, P.; O'Callaghan, A.; Leahy, S.; Bottacini, F.; Molloy, E.; Plattner, S.;
660 Schiavi, E.; Gleinser, M.; Groeger, D.; et al. Genome Analysis and Characterisation of the
661 Exopolysaccharide Produced by *Bifidobacterium longum* subsp. *longum* 35624. *PLoS One*
662 **2016**, *11* (9), e0162983. DOI: 10.1371/journal.pone.0162983.

663 (14) Schiavi, E.; Gleinser, M.; Molloy, E.; Groeger, D.; Frei, R.; Ferstl, R.; Rodriguez-Perez,
664 N.; Ziegler, M.; Grant, R.; Moriarty, T. F.; et al. The Surface-Associated Exopolysaccharide of
665 *Bifidobacterium longum* 35624 Plays an Essential Role in Dampening Host Proinflammatory
666 Responses and Repressing Local TH17 Responses. *Appl Environ Microbiol* **2016**, *82* (24),
667 7185-7196. DOI: 10.1128/AEM.02238-16.

668 (15) Schiavi, E.; Plattner, S.; Rodriguez-Perez, N.; Barcik, W.; Frei, R.; Ferstl, R.; Kurnik-
669 Lucka, M.; Groeger, D.; Grant, R.; Roper, J.; et al. Exopolysaccharide from *Bifidobacterium*
670 *longum* subsp. *longum* 35624 modulates murine allergic airway responses. *Benef Microbes*
671 **2018**, *9* (5), 761-773. DOI: 10.3920/BM2017.0180.

672 (16) Wallimann, A.; Hildebrand, M.; Groeger, D.; Stanic, B.; Akdis, C. A.; Zeiter, S.; Richards,
673 R. G.; Moriarty, T. F.; O'Mahony, L.; Thompson, K. An Exopolysaccharide Produced by
674 *Bifidobacterium longum* 35624(R) Inhibits Osteoclast Formation via a TLR2-Dependent
675 Mechanism. *Calcif Tissue Int* **2021**, *108* (5), 654-666. DOI: 10.1007/s00223-020-00790-4.

676 (17) Boudou, T.; Crouzier, T.; Ren, K.; Blin, G.; Picart, C. Multiple functionalities of
677 polyelectrolyte multilayer films: new biomedical applications. *Adv Mater* **2010**, *22* (4), 441-
678 467. DOI: 10.1002/adma.200901327.

679 (18) Cai, K.; Rechtenbach, A.; Hao, J.; Bossert, J.; Jandt, K. D. Polysaccharide-protein
680 surface modification of titanium via a layer-by-layer technique: characterization and cell
681 behaviour aspects. *Biomaterials* **2005**, *26* (30), 5960-5971. DOI:
682 10.1016/j.biomaterials.2005.03.020.

683 (19) Serizawa, T.; Yamaguchi, M.; Akashi, M. Alternating bioactivity of polymeric layer-by-
684 layer assemblies: anticoagulation vs procoagulation of human blood. *Biomacromolecules*
685 **2002**, *3* (4), 724-731. DOI: 10.1021/bm0200027. Meng, S.; Liu, Z.; Shen, L.; Guo, Z.; Chou,
686 L. L.; Zhong, W.; Du, Q.; Ge, J. The effect of a layer-by-layer chitosan-heparin coating on the
687 endothelialization and coagulation properties of a coronary stent system. *Biomaterials* **2009**,
688 *30* (12), 2276-2283. DOI: 10.1016/j.biomaterials.2008.12.075.

689 (20) Yao Shu, G. O., 2 Li Wang,3 Jingcai Zou,1 and Quanli Li4. Surface Modification of
690 Titanium with Heparin-Chitosan Multilayers via Layer-by-Layer Self-Assembly Technique.
691 *Journal of Nanomaterials* **2010**, *Volue 2011*. DOI: doi:10.1155/2011/423686.

692 (21) Fu, J.; Ji, J.; Yuan, W.; Shen, J. Construction of anti-adhesive and antibacterial
693 multilayer films via layer-by-layer assembly of heparin and chitosan. *Biomaterials* **2005**, *26*
694 (33), 6684-6692. DOI: 10.1016/j.biomaterials.2005.04.034.

695 (22) Angela Mutschler, ‡ Lorene Tallet, †,‡ Morgane Rabineau,†,‡ Camille Dollinger,†,§;
696 Marie-Hel ne Metz-Boutigue, ‡ Francis Schneider,†,|| Bernard Senger,†,‡ Nihal Engin
697 Vrana,†,§; Pierre Schaaf, ‡,⊥ and Philippe Lavalley*,†,‡. Unexpected Bactericidal Activity of
698 Poly(arginine)/Hyaluronan Nanolayered Coatings. *Chem. Mater.* **2016**, *28*, 8700-8709.

699 (23) Antmen, E.; Muller, C. B.; Calligaro, C.; Dupret-Bories, A.; Barthes, J.; Lavalley, P.;
700 Vrana, N. E. In vitro two-step granuloma formation model for testing innate immune response
701 to implants and coatings. *Biomater Adv* **2022**, *138*, 212872. DOI:
702 10.1016/j.bioadv.2022.212872.

703 (24) Liam O'Mahony, S. P., Friedrich Altmann, Paul Kosma. USE OF BIFIDOBACTERIUM
704 LONGUM AND AN EXOPOLYSACCHARIDE PRODUCED THEREBY. US 2018.

705 (25) Yan, Y.; Chang, S.; Wang, T.; Geng, Y. Scratch on Polymer Materials Using AFM Tip-
706 Based Approach: A Review. *Polymers (Basel)* **2019**, *11* (10). DOI: 10.3390/polym11101590.

707 (26) J.L. Hutter, J. B. Calibration of atomic-force microscope tip. *Rev. Sci. Instrum.* **1993**, *64*,
708 1868-1873.

709 (27) Meredith, D. O.; Eschbach, L.; Wood, M. A.; Riehle, M. O.; Curtis, A. S. G.; Richards, R.
710 G. Human fibroblast reactions to standard and electropolished titanium and Ti-6Al-7Nb, and
711 electropolished stainless steel. *Journal of Biomedical Materials Research Part A* **2005**, *75a*
712 (3), 541-555. DOI: 10.1002/jbm.a.30457.

713 (28) Nwodo, U. U.; Green, E.; Okoh, A. I. Bacterial exopolysaccharides: functionality and
714 prospects. *Int J Mol Sci* **2012**, *13* (11), 14002-14015. DOI: 10.3390/ijms131114002.

715 (29) Swain, S. K.; Dey, R. K.; Islam, M.; Patel, R. K.; Jha, U.; Patnaik, T.; Airoidi, C. Removal
716 of Fluoride from Aqueous Solution Using Aluminum-Impregnated Chitosan Biopolymer. *Sep*
717 *Sci Technol* **2009**, *44* (9), 2096-2116. DOI: 10.1080/01496390902881212. Aïder, N. S. M.
718 Zeta Potential and Turbidimetry Analyzes for the Evaluation of Chitosan/Phytic Acid Complex
719 Formation. *Journal of Food Research* **2014**, *3*. DOI: doi:10.5539/jfr.v3n2p71.
720 (30) B. Maciel, C. O., N. Willenbacher Chain flexibility and dynamics of alginate solutions in
721 different solvents. *Colloid and Polymer Science* **2020**, *298*, 791–801.
722 (31) Caridade, S. G.; Monge, C.; Almodovar, J.; Guillot, R.; Lavaud, J.; Josserand, V.; Coll, J.
723 L.; Mano, J. F.; Picart, C. Myoconductive and osteoinductive free-standing polysaccharide
724 membranes. *Acta Biomater* **2015**, *15*, 139-149. DOI: 10.1016/j.actbio.2014.12.027.
725 Schneider, A.; Richert, L.; Francius, G.; Voegel, J. C.; Picart, C. Elasticity, biodegradability
726 and cell adhesive properties of chitosan/hyaluronan multilayer films. *Biomed Mater* **2007**, *2*
727 (1), S45-51. DOI: 10.1088/1748-6041/2/1/S07.
728 (32) Seon, L.; Parat, A.; Gaudiere, F.; Voegel, J. C.; Auzely-Velty, R.; Lorchat, P.; Coche-
729 Guerente, L.; Senger, B.; Schaaf, P.; Jierry, L.; et al. Influence of the interaction strength
730 between supramolecular complexes on the topography of neutral polymer multilayer films.
731 *Langmuir* **2014**, *30* (22), 6479-6488. DOI: 10.1021/la501403m.
732 (33) Boddohi, S.; Killingsworth, C. E.; Kipper, M. J. Polyelectrolyte multilayer assembly as a
733 function of pH and ionic strength using the polysaccharides chitosan and heparin.
734 *Biomacromolecules* **2008**, *9* (7), 2021-2028. DOI: 10.1021/bm8002573.
735 (34) Picart, C.; Mutterer, J.; Richert, L.; Luo, Y.; Prestwich, G. D.; Schaaf, P.; Voegel, J. C.;
736 Lavallo, P. Molecular basis for the explanation of the exponential growth of polyelectrolyte
737 multilayers. *Proc Natl Acad Sci U S A* **2002**, *99* (20), 12531-12535. DOI:
738 10.1073/pnas.202486099.
739 (35) Almodovar, J.; Place, L. W.; Gogolski, J.; Erickson, K.; Kipper, M. J. Layer-by-layer
740 assembly of polysaccharide-based polyelectrolyte multilayers: a spectroscopic study of
741 hydrophilicity, composition, and ion pairing. *Biomacromolecules* **2011**, *12* (7), 2755-2765.
742 DOI: 10.1021/bm200519y.
743 (36) Crouzier, T.; Picart, C. Ion pairing and hydration in polyelectrolyte multilayer films
744 containing polysaccharides. *Biomacromolecules* **2009**, *10* (2), 433-442. DOI:
745 10.1021/bm8012378.
746 (37) Zhang, W.; Yang, Y.; Cui, B. New perspectives on the roles of nanoscale surface
747 topography in modulating intracellular signaling. *Curr Opin Solid State Mater Sci* **2021**, *25*
748 (1). DOI: 10.1016/j.cossms.2020.100873.
749 (38) Wells, R. G. The role of matrix stiffness in regulating cell behavior. *Hepatology* **2008**, *47*
750 (4), 1394-1400. DOI: 10.1002/hep.22193.
751 (39) Liu, L. Y.; Chen, X. D.; Wu, B. Y.; Jiang, Q. [Influence of Aloe polysaccharide on
752 proliferation and hyaluronic acid and hydroxyproline secretion of human fibroblasts in vitro].
753 *Zhong Xi Yi Jie He Xue Bao* **2010**, *8* (3), 256-262. DOI: 10.3736/jcim20100310.
754 (40) Sahana, T. G.; Rekha, P. D. A bioactive exopolysaccharide from marine bacteria
755 *Alteromonas* sp. PRIM-28 and its role in cell proliferation and wound healing in vitro. *Int J*
756 *Biol Macromol* **2019**, *131*, 10-18. DOI: 10.1016/j.ijbiomac.2019.03.048.
757 (41) Tran, P. A.; Webster, T. J. Understanding the wetting properties of nanostructured
758 selenium coatings: the role of nanostructured surface roughness and air-pocket formation. *Int*
759 *J Nanomedicine* **2013**, *8*, 2001-2009. DOI: 10.2147/IJN.S42970.
760 (42) Harvey, A. G.; Hill, E. W.; Bayat, A. Designing implant surface topography for improved
761 biocompatibility. *Expert Rev Med Devices* **2013**, *10* (2), 257-267. DOI: 10.1586/erd.12.82.
762 (43) Lampin, M.; Warocquier, C.; Legris, C.; Degrange, M.; Sigot-Luizard, M. F. Correlation
763 between substratum roughness and wettability, cell adhesion, and cell migration. *J Biomed*
764 *Mater Res* **1997**, *36* (1), 99-108. DOI: 10.1002/(sici)1097-4636(199707)36:1<99::aid-
765 jbm12>3.0.co;2-e.
766 (44) Tamada, Y.; Ikada, Y. Fibroblast growth on polymer surfaces and biosynthesis of
767 collagen. *J Biomed Mater Res* **1994**, *28* (7), 783-789. DOI: 10.1002/jbm.820280705. Kang, I.
768 K.; Ito, Y.; Sisido, M.; Imanishi, Y. Attachment and growth of fibroblast cells on polypeptide
769 derivatives. *J Biomed Mater Res* **1989**, *23* (2), 223-239. DOI: 10.1002/jbm.820230207.

770 (45) den Braber, E. T.; de Ruijter, J. E.; Ginsel, L. A.; von Recum, A. F.; Jansen, J. A.
771 Orientation of ECM protein deposition, fibroblast cytoskeleton, and attachment complex
772 components on silicone microgrooved surfaces. *J Biomed Mater Res* **1998**, *40* (2), 291-300.
773 DOI: 10.1002/(sici)1097-4636(199805)40:2<291::aid-jbm14>3.0.co;2-p. Uttayarat, P.;
774 Toworfe, G. K.; Dietrich, F.; Lelkes, P. I.; Composto, R. J. Topographic guidance of
775 endothelial cells on silicone surfaces with micro- to nanogrooves: orientation of actin
776 filaments and focal adhesions. *J Biomed Mater Res A* **2005**, *75* (3), 668-680. DOI:
777 10.1002/jbm.a.30478. Oakley, C.; Brunette, D. M. The sequence of alignment of
778 microtubules, focal contacts and actin filaments in fibroblasts spreading on smooth and
779 grooved titanium substrata. *J Cell Sci* **1993**, *106* (Pt 1), 343-354. DOI:
780 10.1242/jcs.106.1.343.

781 (46) Chou, S. Y.; Cheng, C. M.; LeDuc, P. R. Composite polymer systems with control of
782 local substrate elasticity and their effect on cytoskeletal and morphological characteristics of
783 adherent cells. *Biomaterials* **2009**, *30* (18), 3136-3142. DOI:
784 10.1016/j.biomaterials.2009.02.037. Engler, A.; Bacakova, L.; Newman, C.; Hategan, A.;
785 Griffin, M.; Discher, D. Substrate compliance versus ligand density in cell on gel responses.
786 *Biophys J* **2004**, *86* (1 Pt 1), 617-628. DOI: 10.1016/S0006-3495(04)74140-5.

787 (47) Tan, L.; Fu, J.; Feng, F.; Liu, X.; Cui, Z.; Li, B.; Han, Y.; Zheng, Y.; Yeung, K. W. K.; Li,
788 Z.; et al. Engineered probiotics biofilm enhances osseointegration via immunoregulation and
789 anti-infection. *Sci Adv* **2020**, *6* (46). DOI: 10.1126/sciadv.aba5723.

790 (48) Davison, N. L., Barrère-de Groot, F., & Grijpma, D. W. . *Degradation of Biomaterials.*;
791 2014.

792 (49) Vasconcelos, D. P.; Costa, M.; Amaral, I. F.; Barbosa, M. A.; Aguas, A. P.; Barbosa, J.
793 N. Modulation of the inflammatory response to chitosan through M2 macrophage polarization
794 using pro-resolution mediators. *Biomaterials* **2015**, *37*, 116-123. DOI:
795 10.1016/j.biomaterials.2014.10.035. Huang, Y. C.; Vieira, A.; Huang, K. L.; Yeh, M. K.;
796 Chiang, C. H. Pulmonary inflammation caused by chitosan microparticles. *J Biomed Mater*
797 *Res A* **2005**, *75* (2), 283-287. DOI: 10.1002/jbm.a.30421.

798 (50) Fong, D.; Hoemann, C. D. Chitosan immunomodulatory properties: perspectives on the
799 impact of structural properties and dosage. *Future Sci OA* **2018**, *4* (1), FSO225. DOI:
800 10.4155/fsoa-2017-0064.

801 (51) Ribeiro, J. C. V.; Forte, T. C. M.; Tavares, S. J. S.; Andrade, F. K.; Vieira, R. S.; Lima, V.
802 The effects of the molecular weight of chitosan on the tissue inflammatory response. *J*
803 *Biomed Mater Res A* **2021**, *109* (12), 2556-2569. DOI: 10.1002/jbm.a.37250.

804 (52) *Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers*. 2012.
805 <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-pyrogen-and-endotoxins-testing-questions-and-answers#:~:text=What%20are%20the%20endotoxins%20limits%20for%20medical%20devices%3F,-The%20Center%20for&text=For%20medical%20devices%2C%20using%20the,cardiovascular%20system%20and%20lymphatic%20system.> (accessed).

811